Mr. Chair, on the C.D. Howe comment, I just answered that question by saying the price management review regime is at the factory gate and not at the consumer level. If the supply is restricted at the consumer level, at the pharmacy the prices would increase.
I hear a bit of speaking from both sides of the mouth from that party. The official critic of the opposition brought a motion forward at the health committee saying “do not act until the committee has made a full study”. Then he presented all possible motions to stop the committee from studying the issue.
The minister is making the moves to do exactly what the House has asked. We all want to ensure that drugs that are manufactured for Canadians are there for the Canadian market. However, it has to be done within the legal framework in the proper way, and that requires consultation. Principles have been laid out. The consultations are on the way. The minister indicated this evening that legislation would come before the House, and I look forward to the member's support for that legislation.